Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported baseline data from its SYMON-II clinical validation study, which includes 777 evaluable patients with an overall 28-day mortality rate of approximately 18%. The study highlighted a diverse population of critically ill patients, with 39.5% meeting Sepsis-3 criteria for septic shock. Among non-survivors, 56.4% had septic shock, indicating greater baseline illness severity compared to survivors. The findings support the evaluation of interleukin-6 (IL-6) as a biomarker for 28-day mortality risk in sepsis patients.